I am privileged to share with you the strides we are making in supporting groundbreaking research into Trigeminal Neuralgia (TN). Our commitment to advancing the understanding and treatment of TN is unwavering, and the Libra Study stands as a testament to this dedication.
The Libra Study, a Phase II/III multicentre clinical trial approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) and an ethics committee, is at the forefront of exploring the efficacy and safety of Basimglurant. This innovative medication, targeting the mGlu5 receptors, offers new hope in mitigating the neural overactivity and pain associated with TN, especially for those who have found little relief with existing treatments.
Understanding the importance of well-informed support and advocacy, we took the initiative to organise a comprehensive training session in London for all our helpline volunteers and regional support leaders. This training was meticulously designed to arm our team with the necessary knowledge to field questions about the trial and to assess its potential benefits for our members. Such informed dialogue is crucial in navigating the complexities of TN treatment options.
The trial itself is structured to rigorously assess Basimglurant’s potential, comprising an initial 8-week run-in phase for dosage adjustment, followed by a 12-week double-blind phase, and culminating in a 52-week open-label extension phase. This meticulous approach ensures a thorough evaluation of the treatment’s efficacy and safety.
Eligibility for the study is thoughtfully considered, extending to adults between 18 to 75 years diagnosed with primary or idiopathic TN. It underscores our aim to reach those most in need of new treatment avenues. The study’s reach, spanning across multiple countries, not only reflects its global impact but also TNA UK’s commitment to fostering international collaboration in TN research.
Moreover, the Libra Study emphasises patient support by covering all related travel and medical expenses, ensuring that participation is accessible to all eligible individuals. This approach is reflective of our broader ethos at TNA UK, where the well-being of our members is paramount.
The feedback from our community has been profoundly positive, with members expressing gratitude for the opportunity to participate in such pivotal research. One member’s words resonate deeply: “A big thank you to our lovely TN association for telling me about the trial. I feel like I can do something for all my fellow sufferers. I am going into the trial full of optimism and hope.” This sentiment captures why we champion such research: to offer hope and make a tangible difference in the lives of those affected by TN.
In closing, the support of our members and the wider community is invaluable as we continue to back significant research endeavours like the Libra Study. It is through these collective efforts that we move closer to uncovering new treatments and ultimately improving the quality of life for those living with Trigeminal Neuralgia.
